IL6 and metabolic dysfunction-associated steatotic liver disease: These findings align with established models linking IL-6 dysregulation to metabolically induced fibrogenic signaling, reinforcing its central role in defining the inflammation-dominant profile of ATD-driven MASLD [14,26].